Format

Send to

Choose Destination
BMC Ophthalmol. 2017 Jun 26;17(1):101. doi: 10.1186/s12886-017-0495-2.

A novel TRPM8 agonist relieves dry eye discomfort.

Author information

1
Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, South Korea.
2
Department of Ophthalmology, Chonnam National University Medical School and Hospital, 42 Jebong-ro, Dong-gu, Gwangju, 61469, South Korea.
3
Department of Anesthesiology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
4
Department of Anesthesiology and Center for the Study of Itch, Washington University, School of Medicine, St. Louis, MO, USA.
5
Alveonix AG, Rotkreuz-Zug, Switzerland.
6
Alta Research LLC, Berkeley, CA, USA.
7
Pavlov Institute of Physiology, 199034, St. Petersburg, Russia.
8
Department of Dermatology, Chonnam National University Medical School and Hospital, 42 Jebong-ro, Dong-gu, Gwangju, 61469, South Korea. seongkim@jnu.ac.kr.
9
Department of Ophthalmology, Chonnam National University Medical School and Hospital, 42 Jebong-ro, Dong-gu, Gwangju, 61469, South Korea. kcyoon@jnu.ac.kr.

Abstract

BACKGROUND:

Physical cooling of the eye surface relieves ocular discomfort, but translating this event to drug treatment of dry eye discomfort not been studied. Here, we synthesized a water-soluble TRPM8 receptor agonist called cryosim-3 (C3, 1-diisopropylphosphorylnonane) which selectively activates TRPM8 (linked to cooling) but not TRPV1 or TRPA1 (linked to nociception) and tested C3 in subjects with mild forms of dry eye disease.

METHODS:

A set of 1-dialkylphosphoryalkanes were tested for activation of TRPM8, TRPV1 and TRPA1 receptors in transfected cells. The bioactivity profiles were compared by perioral, topical, and intravenous delivery to anesthetized rats. The selected lead candidate C3 or vehicle (water) was applied with a cotton gauze pad to upper eyelids of patients with dry eye disease (n = 30). Cooling sensation, tear film break-up time (TBUT), basal tear secretion, and corneal staining were evaluated. C3 was then applied four times daily for 2 weeks to patients using a pre-loaded single unit applicator containing 2 mg/mL of C3 in water (n = 20) or water only. TBUT, basal tear secretion, and corneal staining, and three questionnaires surveys of ocular discomfort (VAS scale, OSDI, and CVS symptoms) were analyzed before and at 1 and 2 weeks thereafter.

RESULTS:

C3 was a selective and potent TRPM8 agonist without TRPV1 or TRPA1 activity. In test animals, the absence of shaking behavior after C3 perioral administration made it the first choice for further study. C3 increased tear secretion in an animal model of dry eye disease and did not irritate when wiped on eyes of volunteers. C3 singly applied (2 mg/ml) produced significant cooling in <5 min, an effecting lasting 46 min with an increase in tear secretion for 60 min. C3 applied for 2 weeks also significantly increased basal tear secretion with questionnaire surveys of ocular discomfort indices clearly showing improvement of symptoms at 1 and 2 weeks. No complaints of irritation or pain were reported by any subject.

CONCLUSIONS:

C3 is a promising candidate for study of TRPM8 function on the eye surface and for relief of dry eye discomfort.

TRIAL REGISTRATION:

ISRCTN24802609 and ISRCTN13359367 . Registered 23 March 2015 and 2 September 2015.

KEYWORDS:

Dry eye; Eyelid; Ocular discomfort; TRPM8

PMID:
28651550
PMCID:
PMC5485613
DOI:
10.1186/s12886-017-0495-2
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center